Astellas Pharma (ALPMY) to Post Earnings on Wednesday

Astellas Pharma (OTCMKTS:ALPMY) is anticipated to release its results after the market closes on Wednesday, August 5th. Analysts expect Astellas Pharma to announce earnings of $0.3336 per share and revenue of $3.4489 billion for the quarter.

Astellas Pharma Price Performance

Shares of OTCMKTS ALPMY opened at $13.73 on Monday. The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average of $13.42 and a 200-day moving average of $14.63. The firm has a market capitalization of $24.85 billion, a price-to-earnings ratio of 12.78 and a beta of 0.08. Astellas Pharma has a 12 month low of $10.03 and a 12 month high of $17.35.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).